Evidence map›Paper›PMID 16170375›Full record

ArticleOncogene2005

Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway.

Kenneth Rogulski, Youjun Li, Kristi Rothermund, Lixia Pu, Simon Watkins, Fenghua Yi, Edward V Prochownik

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Article
  3. Novel Prognostic Markers for Skin Cutaneous Melanoma.Clinical, cosmetic and investigational dermatology · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Multifaced roles of PLAC8 in cancer.Biomarker research · 2021
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kenneth RogulskiSection of Hematology/Oncology, Children's Hospital of Pittsburgh, Pittsburgh, PA 15213, USA.
Youjun Li
Kristi Rothermund
Lixia Pu
Simon Watkins
Fenghua Yi
Edward V Prochownik
Children's Hospital of Pittsburgh · USUPMC Hillman Cancer Center · US

Funding

MOLECULAR BIOLOGY OF HEMATOPOIETIC DIFFERENTIATIONR01HL033741 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PROCHOWNIK, EDWARD V · 1985 to 2000
$341k
NHLBI NIH HHS HL33741
6 · The paper itself

Abstract

The c-Myc oncoprotein is a general transcription factor whose target genes dictate the c-Myc phenotype. One such target of c-Myc, 'onzin', is normally expressed at high levels in myeloid cells and is dramatically downregulated in response to c-Myc overexpression. We show here that short hairpin interfering RNA-mediated knockdown of endogenous onzin results in a reduced growth rate and a proapoptotic phenotype. In contrast, onzin overexpression in fibroblasts is associated with an increased growth rate, resistance to apoptotic stimuli, loss of the G2/M checkpoint, and tumorigenic conversion. Onzin-overexpressing cells fail to induce p53 in response to apoptotic stimuli and contain higher levels of the active, phosphorylated forms of Akt1 and, more strikingly, of Mdm2. Using yeast two-hybrid and coimmunoprecipitation assays, we show that onzin directly interacts with both proteins. Green fluorescent protein tagging also confirms directly that Akt1 and Mdm2 colocalize with onzin, although the precise subcellular distribution of each protein is dependent on its relative abundance. Collectively, our results identify onzin as a novel regulator of several p53-dependent aspects of the c-Myc phenotype via its dramatic effect on Mdm2. This is reminiscent of the c-Myc --> p19(ARF)--mid R: Mdm2 pathway and might function as a complementary arm to ensure the proper cellular response to oncogenic and/or apoptotic stimuli.

Indexed as

Up-RegulationAmino Acid SequenceAnimalsApoptosisCell CycleCell SurvivalChlorocebus aethiopsCOS CellsFibroblastsGenes, p53HumansMiceMolecular Sequence DataOncogene ProteinsPhenotypePhosphorylationAKT1 protein, humanMDM2 protein, humanMYC protein, humanOncogene Proteinsonzin protein, mousePLAC8 protein, humanPlac8 protein, mouseProteinsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mdm2Proto-Oncogene Proteins c-mycTumor Suppressor Protein p53

Identifiers

PMID16170375
OpenAlexW2022930162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.